Human papillomavirus proteins (HPV proteins)

HPV proteins" refers to the family of viral proteins encoded by human papillomavirus (HPV) types, which include both **structural proteins** (L1, L2) and **non-structural/early proteins** (E1, E2, E4, E5, E6, E7)[1][2][3][5]. L1 and L2 form the viral capsid and are the basis of current prophylactic vaccines, eliciting type-specific neutralizing antibodies[2][3][4][5]. The early proteins E6 and E7 are classified as viral oncoproteins that inactivate host tumor suppressors p53 and Rb, respectively, and are implicated in the oncogenesis of various cancers[3][2]. E1 is a viral helicase required for replication; E2 modulates viral transcription and replication[3]. Therapeutic targeting efforts focus on vaccine prevention (L1) and inhibition or immune targeting of E6/E7 (for cancer therapy)[2][3]. The term "HPV proteins" is too broad for drug development purposes, as different proteins have distinct structures and functions, and most drugs or vaccines are specific for L1, E6, or E7—not for all HPV proteins collectively[1][2][3][5], so this entry is not specific enough for a canonical therapeutic target.

Other names

Human papillomavirus structural proteinsHPV L1 proteinHPV L2 proteinHPV E6 proteinHPV E7 proteinHPV E1 proteinHPV E2 proteinHPV E4 proteinHPV E5 protein

Vaccines induce neutralizing antibodies against L1 to prevent infection Investigational drugs seek to inhibit E6 and E7 functions to restore p53 and Rb tumor suppressor activity